Sarepta Therapeutics (SRPT) News Today

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) shares have rallied today, driven by management’s decisive cost-cutting and favorable analyst commentary despite recent setbacks in its gene-therapy program.

• Positive Sentiment: Company unveils a strategic restructuring and pipeline-prioritization plan—cutting about 500 jobs (36% of workforce) and refocusing on high-value programs (including its siRNA platform), expected to save roughly $100 million annually and shore up long-term growth. BusinessWire: Strategic Restructuring Plan
• Positive Sentiment: FDA’s addition of a black-box warning to Elevidys removed uncertainty around safety labeling, a move analysts view as clearing the way for future catalysts and reducing regulatory overhang. Barron's: Why Layoffs and a ‘Black-Box' Warning Are Good News
• Positive Sentiment: Needham & Company LLC reiterates its “Buy” rating and sets a $50.00 price target—implying over 125% upside—on confidence in the company’s revamped pipeline strategy. MarketBeat: Needham Reiterates Buy Rating
• Positive Sentiment: Robert W. Baird ups its price objective from $30.00 to $35.00 and maintains an “Outperform” rating, underscoring optimism about near-term clinical readouts and cost-savings impact. MarketBeat: Baird Raises Price Objective
• Positive Sentiment: Barclays raises its target from $29.00 to $32.00 and assigns an “Overweight” rating, highlighting the financial benefits of the company’s cost-reduction measures. MarketBeat: Barclays Boosts Price Target
• Neutral Sentiment: Royal Bank of Canada trims its target to $23.00 but maintains a “Sector Perform” rating, reflecting mixed views on near-term upside following restructuring news. MarketBeat: RBC Lowers Price Target
• Neutral Sentiment: JPMorgan holds its “Overweight” stance but cuts its price target slightly, signaling confidence tempered by product-related risks. MSN: JPMorgan Cuts PT, Keeps Overweight
• Neutral Sentiment: Multiple law firms (Pomerantz, Gross, Kessler Topaz, Faruqi & Faruqi, Bragar Eagel) issue class-action notices regarding alleged securities-law violations during the June 2023–June 2025 period. PRNewswire: Pomerantz Law Firm Class Action Alert
• Neutral Sentiment: Q2 SG&A expense report released with no material surprises, in line with guidance. GuruFocus: Q2 SG&A Expenses
• Negative Sentiment: Two patient deaths linked to the Duchenne gene therapy Elevidys prompted program halts (e.g., limb-girdle muscular dystrophy), raising safety concerns. Reuters: Sarepta to Cut 500 Jobs After Gene Therapy Setback

Overall, decisive leadership actions and robust analyst support have propelled SRPT higher, even as clinical setbacks and legal inquiries linger.